Verici Dx plc

("Verici Dx" or the "Company")

Agreement with Blue Cross and Blue Shield of Illinois for Tutivia™

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has entered into an agreement ("the agreement") with Blue Cross and Blue Shield ("BCBS") of Illinois for Tutivia™, the Company's post-kidney transplant test focused on early detection of acute rejection.

The agreement ensures that Tutivia is considered as an in-network benefit for patients which streamlines the claims process and ensures that patients receive testing at in-network rates. BCBS also has its own Preferred Provider Organization network, of which Verici Dx is now a member. As a result, the Company receives access to open contract processes with other BCBS entities, including BCBS Texas.

BCBS provides health care coverage for 118 million members in all 50 states, Washington, D.C., and Puerto Rico, and more than 2 million doctors and hospitals contract with BCBS companies nationwide. BCBS has several lines of business in Illinois, including commercial payor, managed Medicaid and Medicare Advantage, all of which are covered as part of the agreement.

The agreement also provides access to the BCBS Association, which covers 33 BCBS member entities. In turn, this allows for a streamlined process for Verici Dx to access a CareSource agreement.

Sara Barrington, Chief Executive Officer, said: "This agreement with BCBS represents a key milestone for Verici Dx as we continue to grow our patient network and focus on expanding our commercial reach. We look forward to updating shareholders further as we progress with this agreement and continue to advance discussions with additional payors."

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.

Operating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.

The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.